Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia Kaklamani

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Clinical Advances in Hematology & Oncology : H&O|January 31, 2024
Sequencing therapies: optimal treatment for HR+/HER2- metastatic breast cancerVirginia Kaklamani
Expert Review of Molecular Diagnostics|December 5, 2006
A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DXVirginia Kaklamani
Leukemia & Lymphoma|May 26, 2010
Can novel genetic polymorphisms predict response to therapy in acute myeloid leukemia?Virginia Kaklamani
Cancer Treatment and Research|October 8, 2005
Transforming Growth Factor Beta and breast cancerVirginia Kaklamani, Boris Pasche
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Updates on the preoperative immunotherapy for triple-negative breast cancerHong Hu, Virginia Kaklamani
JAMA|September 3, 2010
Lessons learned from genetic testingLaura Esserman, Virginia Kaklamani
Expert Review of Anticancer Therapy|August 26, 2010
Lapatinib and breast cancer: current indications and outlook for the futureCynthia Moreira, Virginia Kaklamani
Current Treatment Options in Oncology|August 23, 2021
Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer RiskAnusha Vaidyanathan, Virginia Kaklamani
Seminars in Oncology|May 5, 2004
New targeted therapies in breast cancerVirginia Kaklamani, Ruth M O'Regan
Future Oncology (London, England)|March 21, 2019
Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancerJoyce O'Shaughnessy, Virginia Kaklamani, Kevin Kalinsky
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Clinical Advances in Hematology & Oncology : H&O|January 31, 2024
Sequencing therapies: optimal treatment for HR+/HER2- metastatic breast cancerVirginia Kaklamani
Expert Review of Molecular Diagnostics|December 5, 2006
A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DXVirginia Kaklamani
Leukemia & Lymphoma|May 26, 2010
Can novel genetic polymorphisms predict response to therapy in acute myeloid leukemia?Virginia Kaklamani
Cancer Treatment and Research|October 8, 2005
Transforming Growth Factor Beta and breast cancerVirginia Kaklamani, Boris Pasche
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Updates on the preoperative immunotherapy for triple-negative breast cancerHong Hu, Virginia Kaklamani
JAMA|September 3, 2010
Lessons learned from genetic testingLaura Esserman, Virginia Kaklamani
Expert Review of Anticancer Therapy|August 26, 2010
Lapatinib and breast cancer: current indications and outlook for the futureCynthia Moreira, Virginia Kaklamani
Current Treatment Options in Oncology|August 23, 2021
Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer RiskAnusha Vaidyanathan, Virginia Kaklamani
Seminars in Oncology|May 5, 2004
New targeted therapies in breast cancerVirginia Kaklamani, Ruth M O'Regan
Future Oncology (London, England)|March 21, 2019
Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancerJoyce O'Shaughnessy, Virginia Kaklamani, Kevin Kalinsky
Pageof 7